Zoledronic Acid Modulation of TRPV1 Channel Currents in Osteoblast Cell Line and Native Rat and Mouse Bone Marrow-Derived Osteoblasts: Cell Proliferation and Mineralization Effect [PDF]
, 2019 Rosa Scala +6 more
openalex +1 more source
Supplementary Figure 4 from Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment <i>In Vivo</i> [PDF]
, 2023 Penelope D. Ottewell +7 more
openalex +1 more source
Severe increase in creatinine with hypocalcaemia in thalidomide‐treated myeloma patients receiving zoledronic acid infusions [PDF]
, 2002 Stephen G. Jones +3 more
openalex +1 more source
Risks and benefits in using zoledronic acid in patients with bone metastases [PDF]
, 2012 Dalia Zayed, Niveen Abo-Touk
openalex +1 more source
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
Clinical Interventions in Aging, 2008 Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, GreeceAbstract: Zoledronic acid is a nitrogen-containing, third-generation ...
Irene Lambrinoudaki +4 more
doaj
Bone Loss after Allogeneic Haematopoietic Stem Cell Transplantation: A Pilot Study on the Use of Zoledronic Acid [PDF]
, 2012 Andreas Hausmann +9 more
openalex +1 more source
Zoledronic acid in the management of metastatic bone disease
Therapeutics and Clinical Risk Management, 2008 Thomas J Polascik, Vladimir MouravievDuke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC, USAAbstract: Many patients with advanced cancer experience decreased bone strength due to metastatic foci, underlying ...
Thomas J Polascik, Vladimir Mouraviev
doaj
Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis [PDF]
, 2013 Zoledronic acid, a bisphosphonate, has been approved for treatment and prevention of osteoporosis. This case describes a 73-year-old woman with primary osteoporosis who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment.
Fang, Fusheng +9 more
core
Identifying therapeutic biomarkers of zoledronic acid by metabolomics [PDF]
, 2023 Xiang Li +8 more
openalex +1 more source